Streetbeat News

Analyst Ratings

DAVA

Morgan Stanley analyst James Faucette reiterated an Overweight rating on Endava (NYSE:DAVA) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:19 pm

BFAM

Morgan Stanley analyst Toni Kaplan maintains an Underweight rating on Bright Horizons Family (NYSE:BFAM) and raises the price target from $57 to $61.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:19 pm

TSLA

Goldman Sachs downgraded Tesla from a Buy to a Neutral rating, citing the stock's substantial surge as a reason. The firm raised the 12-month price target from $185 to $248, which is lower than Tesla's current market price of $256.

Portfolio Pulse from Piero Cingari

June 26, 2023 | 1:18 pm

BNTX

Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a $124 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:18 pm

ASND

Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $109 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:17 pm

AMH

Morgan Stanley analyst Adam Kramer maintains an Equal-Weight rating on American Homes 4 Rent (NYSE:AMH) and raises the price target from $31.5 to $34.5.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:17 pm

SONN

EF Hutton analyst Michael King reiterates a Buy rating on Sonnet BioTherapeutics (NASDAQ:SONN) and maintains a $6.7 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 1:16 pm

PI

BWS Financial analyst Hamed Khorsand initiates coverage on Impinj (NASDAQ:PI) with a Sell rating and a price target of $45.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 1:10 pm

ABBV

OGN

VTRS

Three health care stocks with over 4% dividend yields have been highlighted by Wall Street's most accurate analysts. Organon & Co. (OGN) has a 5.36% dividend yield, Viatris Inc. (VTRS) has a 4.78% dividend yield, and AbbVie Inc. (ABBV) has a 4.31% dividend yield. Recent news includes worse-than-expected Q1 results for OGN, better-than-expected earnings for VTRS, and a positive recommendation for ABBV's Atogepant by the European Medicines Agency.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 1:08 pm